Immune-mediated Myositis Following Gene Therapy for Duchenne Muscular Dystrophy: a Case Report

Overview

Journal J Neurol

Specialty Neurology

Date 2024 Jun 21

PMID 38907024

Authors

Susan T Iannaccone

Chunyu Cai

Brittney Rhem

Kaitlin Batley

Veena Rajaram

Benjamin M Greenberg

Sachi Dharia

Craig M Zaidman

Affiliations

Soon will be listed here.

Citing Articles

Enhanced expression of dystrophin, IGF-1, CD44 and MYH3 in plasma and skeletal muscles including diaphragm of mdx mice after oral administration of Neu REFIX beta 1,3-1,6 glucan.

Preethy S, Sakamoto S, Higuchi T, Ichiyama K, Yamamoto N, Ikewaki N Sci Rep. 2025; 15(1):7232.

PMID: 40021828 PMC: 11871006. DOI: 10.1038/s41598-025-92258-4.

Immunologic investigations into transgene directed immune-mediated myositis following delandistrogene moxeparvovec gene therapy.

Potter R, Moeller I, Khan S, Haegel H, Hollenstein A, Steiner G Sci Rep. 2025; 15(1):4.

PMID: 39747998 PMC: 11696689. DOI: 10.1038/s41598-024-84077-w.

References

Matthews E, Brassington R, Kuntzer T, Jichi F, Manzur A . Corticosteroids for the treatment of Duchenne muscular dystrophy. Cochrane Database Syst Rev. 2016; (5):CD003725. PMC: 8580515. DOI: 10.1002/14651858.CD003725.pub4. View

Takeda S, Clemens P, Hoffman E . Exon-Skipping in Duchenne Muscular Dystrophy. J Neuromuscul Dis. 2021; 8(s2):S343-S358. PMC: 8673534. DOI: 10.3233/JND-210682. View

Mendell J, Rodino-Klapac L, Sahenk Z, Malik V, Kaspar B, Walker C . Gene therapy for muscular dystrophy: lessons learned and path forward. Neurosci Lett. 2012; 527(2):90-9. PMC: 3492936. DOI: 10.1016/j.neulet.2012.04.078. View

Mendell J, Sahenk Z, Lehman K, Nease C, Lowes L, Miller N . Assessment of Systemic Delivery of rAAVrh74.MHCK7.micro-dystrophin in Children With Duchenne Muscular Dystrophy: A Nonrandomized Controlled Trial. JAMA Neurol. 2020; 77(9):1122-1131. PMC: 7296461. DOI: 10.1001/jamaneurol.2020.1484. View

Mendell J, Campbell K, Rodino-Klapac L, Sahenk Z, Shilling C, Lewis S . Dystrophin immunity in Duchenne's muscular dystrophy. N Engl J Med. 2010; 363(15):1429-37. PMC: 3014106. DOI: 10.1056/NEJMoa1000228. View

Bonnemann C, Belluscio B, Braun S, Morris C, Singh T, Muntoni F . Dystrophin Immunity after Gene Therapy for Duchenne's Muscular Dystrophy. N Engl J Med. 2023; 388(24):2294-2296. DOI: 10.1056/NEJMc2212912. View

Padmanabhan A, Connelly-Smith L, Aqui N, Balogun R, Klingel R, Meyer E . Guidelines on the Use of Therapeutic Apheresis in Clinical Practice - Evidence-Based Approach from the Writing Committee of the American Society for Apheresis: The Eighth Special Issue. J Clin Apher. 2019; 34(3):171-354. DOI: 10.1002/jca.21705. View

Shieh P . Emerging Strategies in the Treatment of Duchenne Muscular Dystrophy. Neurotherapeutics. 2018; 15(4):840-848. PMC: 6277306. DOI: 10.1007/s13311-018-00687-z. View

Flanigan K, Campbell K, Viollet L, Wang W, Gomez A, Walker C . Anti-dystrophin T cell responses in Duchenne muscular dystrophy: prevalence and a glucocorticoid treatment effect. Hum Gene Ther. 2013; 24(9):797-806. PMC: 3768239. DOI: 10.1089/hum.2013.092. View

10.

Chicoine L, Montgomery C, Bremer W, Shontz K, Griffin D, Heller K . Plasmapheresis eliminates the negative impact of AAV antibodies on microdystrophin gene expression following vascular delivery. Mol Ther. 2013; 22(2):338-347. PMC: 3916040. DOI: 10.1038/mt.2013.244. View